- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT00132028
Vorinostat in Treating Patients With Relapsed or Refractory Advanced Hodgkin's Lymphoma
A Phase II Trial of Suberoylanilide Hydroxamic Acid (NSC-701852) for Recurrent or Primary Refractory Hodgkin's Lymphoma
Panoramica dello studio
Stato
Condizioni
- Linfoma di Hodgkin dell'adulto ricorrente
- Linfoma di Hodgkin a deplezione di linfociti adulti
- Linfoma di Hodgkin a predominanza dei linfociti adulti
- Linfoma di Hodgkin a cellula mista dell'adulto
- Sclerosi nodulare adulta Linfoma di Hodgkin
- Linfoma di Hodgkin predominante nei linfociti nodulari dell'adulto
- Adult Favorable Prognosis Hodgkin Lymphoma
- Adult Unfavorable Prognosis Hodgkin Lymphoma
Intervento / Trattamento
Descrizione dettagliata
PRIMARY OBJECTIVES:
I. To evaluate the response probability (complete, complete unconfirmed, and partial) in patients with relapsed or refractory Hodgkin's lymphoma.
II. To estimate 1-year progression-free survival and overall survival in patients with relapsed or refractory Hodgkin's lymphoma treated with SAHA.
III. To assess the toxicity profile of SAHA in this patient population. IV. To perform gene expression profiling on tumor tissue before and after treatment in order to explore in a preliminary manner the association between response and specific gene expression results.
OUTLINE: This is a multicenter study.
Patients receive oral vorinostat twice daily on days 1-14. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity. Patients achieving a complete response (CR) receive 2 additional courses of therapy beyond CR.
After completion of study treatment, patients are followed every 6 months for 2 years and then annually for 3 years.
Tipo di studio
Iscrizione (Effettivo)
Fase
- Fase 2
Contatti e Sedi
Luoghi di studio
-
-
Texas
-
San Antonio, Texas, Stati Uniti, 78245
- Southwest Oncology Group (SWOG) Research Base
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Patients must have histologically or cytologically confirmed relapsed/refractory Hodgkin's lymphoma of any subtype; patients with lymphocyte predominant Hodgkin's disease (LPHD) are also eligible; clear evidence of disease progression or lack of response after the most recent therapy, including local radiation is required
- Patients must be willing to submit specimens for correlative studies
- All patients must have bidimensionally measurable disease documented within 28 days prior to registration; patients with non-measurable disease in addition to measurable disease must have all non-measurable disease assessed within 42 days prior to registration
- Patients must have unilateral bone marrow aspirate and biopsy performed within 42 days prior to registration
- Patients may have had up to five prior chemotherapy regimens
- Patients must have completed chemotherapy at least 28 days prior to registration and all toxicities must have resolved (in the opinion of the treating investigator); if last regimen included nitrosoureas or mitomycin then 42 days must have elapsed since completion of treatment; patients must not have taken valproic acid, or another histone deacetylase inhibitor, for at least 14 days prior to registration
- Patients must have completed all radiotherapy at least 14 days prior to registration and all toxicities must have resolved (in the opinion of the treating investigator)
- Patients who relapse after autologous stem cell transplant may be enrolled if they are at least three months after transplant, and after allogeneic transplant if they are at least one year posttransplant; patients should have no active related infections (i.e., fungal or viral); in the case of allogeneic transplant relapse, there should be no active acute graft versus host disease (GvHD) of any grade, and no chronic graft versus host disease other than mild skin, oral, or ocular GvHD not requiring systemic immunosuppression
- Patients must have a Zubrod performance status of 0-2
- Patients must have a CT scan of the chest/abdomen and pelvis performed within 28 days prior to registration
- Patients must not have clinical evidence of central nervous system involvement by lymphoma; any laboratory or radiographic tests performed to assess CNS involvement must be negative within 42 days of registration
- Serum LDH must be measured within 28 days prior to registration
- Absolute neutrophil count >- 1,000/mcL
- Platelet count >= 100,000/mcL
- SGOT/SGPT < 2.5 x the institutional upper limit of normal
- Serum creatinine < 2 x the institutional upper limit of normal
- Patients with a history of allergic reactions attributed to compounds of similar chemical or biological composition to SAHA are ineligible
- Patients must not have plans to receive concurrent hormonal, biological or radiation therapy; patients with potentially curative options such as salvage therapy with chemotherapy or hematopoietic stem cell transplant (HSCT) are not eligible
- Patients with a history of prior myocardial infarction, unstable angina, or stroke within 6 months are ineligible
- Patients known to be HIV-positive and receiving combination antiretroviral therapy are ineligible; in addition, HIV-positive patients not receiving combination antiretroviral therapy are also ineligible
- No prior malignancy is allowed except for the following: adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, adequately treated stage I or II cancer from which the patient is currently in complete remission, or any other cancer for which the patient has been disease-free for five years
- Pregnant or nursing women may not participate; women or men of reproductive potential may not participate unless they have agreed to use an effective contraceptive method
- Patients must be informed of the investigational nature of this study and must sign and give written informed consent in accordance with institutional and federal guidelines
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: N / A
- Modello interventistico: Assegnazione di gruppo singolo
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
---|---|
Sperimentale: Treatment (vorinostat)
Patients receive oral vorinostat twice daily on days 1-14.
Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.
Patients achieving a complete response (CR) receive 2 additional courses of therapy beyond CR.
|
Studi correlati
Dato oralmente
Altri nomi:
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
Assess Number of Patients Who Achieve Confirmed and Unconfirmed Complete Response (CR) or Partial Response (PR)
Lasso di tempo: after every 3 cycles on treatment
|
Complete Response(CR) is a complete disappearance of all disease with the exception of nodes.
No new lesions.
previously enlarged organs must have regressed and not be palpable.
Bone marrow(BM) must be negative if positive at baseline.
Normalization of markers.
CR Unconfirmed (CRU) does not qualify for CR above, due to a residual nodal mass or an indeterminate BM.
Partial Response(PR) is a 50% decrease in the SPD for up to 6 identified dominant lesions, including spleenic and hepatic nodules from baseline.
No new lesions and no increase in the size of liver, spleen or other nodes.
|
after every 3 cycles on treatment
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
Progression-Free Survival
Lasso di tempo: after every 3 cycles on treatment, then every 6 months for 2 years, then annually for a total of 5 years.
|
Measured from date of registration to date of first observation of progression or death, or last contact date.
Progression is defined as a 50% increase in sum of products of greatest diameters (SPD) of target measurable lesions over the smallest sum observed (over baseline if no decrease during therapy) using the same techniques as baseline; appearance of a new lesion/site; unequivocal progression of non-measurable disease in the opinion of the treating physician; death due to disease without prior documentation of progression.
|
after every 3 cycles on treatment, then every 6 months for 2 years, then annually for a total of 5 years.
|
Overall Survival
Lasso di tempo: after every 3 cycles on treatment, then every 6 months for 2 years, then annually for a total of 5 years.
|
Measured from date of registration to death, or last contact date
|
after every 3 cycles on treatment, then every 6 months for 2 years, then annually for a total of 5 years.
|
Collaboratori e investigatori
Sponsor
Investigatori
- Investigatore principale: Mark Kirschbaum, Southwest Oncology Group
Studiare le date dei record
Studia le date principali
Inizio studio
Completamento primario (Effettivo)
Completamento dello studio (Effettivo)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Stima)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Stima)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
- Malattie del sistema immunitario
- Neoplasie per tipo istologico
- Neoplasie
- Malattie linfoproliferative
- Malattie linfatiche
- Disturbi immunoproliferativi
- Linfoma
- Malattia di Hodgkin
- Meccanismi molecolari dell'azione farmacologica
- Inibitori enzimatici
- Agenti antineoplastici
- Inibitori dell'istone deacetilasi
- Vorinostat
Altri numeri di identificazione dello studio
- NCI-2012-03071 (Identificatore di registro: CTRP (Clinical Trial Reporting Program))
- U10CA032102 (Sovvenzione/contratto NIH degli Stati Uniti)
- S0517 (Altro identificatore: CTEP)
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .
Prove cliniche su analisi di laboratorio dei biomarcatori
-
ORIOL BESTARDCompletatoTrapianto di rene | Infezione da CMVSpagna, Belgio
-
Progenity, Inc.CompletatoSindrome di Down | Aneuploidia | Sindrome di DiGeorge | Sindrome di Turner | Sindrome di Klinefelter | Delezione cromosomica | Sindrome di Edwards | Sindrome di PatauStati Uniti
-
Vanderbilt University Medical Center4DMedicalCompletato
-
RWTH Aachen UniversitySconosciutoEmorragia subaracnoidea aneurismaticaGermania
-
Central and North West London NHS Foundation TrustBritish HIV Association (BHIVA)Non ancora reclutamentoInfezioni da HIV | Epatite B
-
Bakirkoy Dr. Sadi Konuk Research and Training HospitalReclutamento
-
University of MiamiAttivo, non reclutante
-
Universidad Miguel Hernandez de ElcheInstitut Català de la Salut; Andaluz Health Service; Osakidetza; Servicio Madrileño... e altri collaboratoriCompletatoMalattie professionaliSpagna
-
Rio de Janeiro State UniversityCoordenação de Aperfeiçoamento de Pessoal de Nível Superior.; Conselho Nacional... e altri collaboratoriCompletatoMalattia cardiovascolare | Carenza di vitamina D | Condizioni correlate alla menopausaBrasile
-
RenJi HospitalSconosciutoCarcinoma a cellule squamose dell'esofagoCina